Oncology Precision Medicine Market Report 2026

The oncology precision medicine market size has grown rapidly in recent years. It will grow from $125.14 billion in 2025 to $141.22 billion in 2026 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to limited availability of genomic testing, reliance on standard chemotherapy protocols, increasing cancer prevalence, early development of molecular diagnostics, adoption of hospital-based oncology research programs.

The oncology precision medicine market size is expected to see rapid growth in the next few years. It will grow to $226.55 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to advancements in CAR-T and gene therapies, growth in targeted kinase and immune checkpoint inhibitors, rising investments in precision oncology research, integration of bioinformatics and AI in clinical decision-making, expansion of biomarker-guided clinical trials. Major trends in the forecast period include rising adoption of personalized cancer therapies, increasing use of companion diagnostics and molecular diagnostics, growth in liquid biopsy and next-generation sequencing assays, expansion of targeted therapeutics and monoclonal antibodies, increasing focus on biomarker-based patient stratification.

The rising prevalence of cancer is expected to drive growth in the oncology precision medicine market in the coming years. Cancer is a condition in which abnormal cells grow uncontrollably and may spread to other parts of the body, disrupting normal physiological functions. Its increasing prevalence is largely attributed to aging populations, as longer lifespans lead to the accumulation of DNA mutations, weakened repair mechanisms, chronic inflammation, reduced immune surveillance, and tissue environments that support tumor growth. Oncology precision medicine addresses cancer by offering personalized treatments tailored to the unique genetic profile of each tumor, enhancing treatment efficacy while minimizing side effects. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that the estimated 20 million new cancer cases in 2022 are projected to rise by 77% to over 35 million cases by 2050. This demonstrates that the increasing prevalence of cancer is fueling the oncology precision medicine market.

Key companies in the oncology precision medicine market are focusing on innovative approaches, such as molecular tumor board initiatives, to enable multidisciplinary collaboration and optimize personalized treatment plans. Molecular tumor boards are teams of experts who analyze complex genetic and molecular data to recommend individualized cancer therapies. For instance, in April 2025, McKesson Corporation, a U.S.-based healthcare services and IT company, launched the Precision Care Companion initiative to support biomarker-driven cancer care. The program combines education, technological enhancements, and operational support for oncology practices, bringing together physicians, clinical staff, business leaders, and pharmaceutical partners to integrate advanced genomic testing and targeted therapies more efficiently, thereby improving patient outcomes.

In February 2024, AbbVie Inc., a U.S.-based biopharmaceutical company, acquired ImmunoGen for $10.1 billion. This acquisition allows AbbVie to strengthen its oncology portfolio and accelerate its presence in the solid tumor segment by leveraging ImmunoGen’s commercial infrastructure, global reach, and antibody-drug conjugate pipeline beyond ovarian cancer. ImmunoGen Inc., a U.S.-based biotechnology firm, develops antibody-drug conjugates that deliver precision-targeted cancer therapies based on specific tumor biomarkers.

Major companies operating in the oncology precision medicine market are Roche Holding AG, Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, Gilead Sciences Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Almac Group Limited, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Pacific Biosciences of California Inc., Asuragen Inc., BGI Group, ANGLE plc.

North America was the largest region in the oncology precision medicine market in 2025. The regions covered in the oncology precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncology precision medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the oncology precision medicine market by increasing costs for imported diagnostic instruments, sequencing equipment, and therapeutic biologics. Segments such as next-generation sequencing assays, CAR-T therapies, and monoclonal antibodies are particularly impacted, with North America, Europe, and Asia-Pacific regions like China and India experiencing significant price adjustments. While tariffs pose supply chain challenges and elevate production costs, they also drive local manufacturing initiatives, domestic innovation, and regional investment in precision medicine infrastructure.

The oncology precision medicine market research report is one of a series of new reports that provides oncology precision medicine market statistics, including oncology precision medicine industry global market size, regional shares, competitors with a oncology precision medicine market share, detailed oncology precision medicine market segments, market trends and opportunities, and any further data you may need to thrive in the oncology precision medicine industry. This oncology precision medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oncology precision medicine is a personalized approach to cancer care that utilizes genetic, molecular, and clinical information to tailor treatment strategies to the specific characteristics of each patient’s tumor. Its goal is to improve outcomes by selecting therapies that precisely target the unique biological features of a patient’s cancer, resulting in more effective and less toxic treatments.

The main product types in oncology precision medicine include diagnostics, therapeutics, inhibitor drugs, monoclonal antibodies, cell and gene therapies, and antiviral and antiretroviral drugs. Diagnostics involves identifying diseases or medical conditions through examination, testing, and analysis of symptoms or biological samples. Key technologies include genomics, proteomics, bioinformatics, and others. Biomarker types include genetic, protein, epigenetic, and metabolic biomarkers, among others. Applications cover a range of cancers, including breast, lung, colorectal, prostate, cervical, kidney, liver, bladder cancers, and more. These products are utilized by multiple end users, including hospitals, diagnostic laboratories, research institutions, pharmaceutical companies, and others.

The oncology precision medicine market consists of revenues earned by entities by providing services such as personalized treatment planning, molecular tumor profiling services, companion diagnostics services, clinical decision support services, and patient risk assessment and stratification. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncology precision medicine market also includes sales of next-generation sequencing (NGS) machines, polymerase chain reaction (PCR) systems, flow cytometers, and robotic sample preparation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.